This article is more than 5 years old. Information may no longer be current.

EyePoint announces public offering pricing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyePoint Pharmaceuticals is offering 10,526,500 shares of its common stock at $1.90 per share, the company announced in a press release.

Gross proceeds from the public offering are expected to be approximately $20 million, and the company granted the underwriters a 30-day option to purchase up to an additional 1,578,975 shares, the release said.

Net proceeds will be used to fund the commercialization of Dexycu (dexamethasone intraocular suspension 9%) and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg).

The offer is expected to close on or about April 1.